Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity

The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the p...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Werner, Rudolf A., Lapa, Constantin, Ilhan, Harun, Higuchi, Takahiro, Buck, Andreas K., Lehner, Sebastian, Bartenstein, Peter, Bengel, Frank, Schatka, Imke, Muegge, Dirk O., Papp, László, Zsótér, Norbert, Große-Ophoff, Tobias, Essler, Markus, Bundschuh, Ralph A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Clinical Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351689/
https://ncbi.nlm.nih.gov/pubmed/27705948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12402
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia